Sepracor president told analysts that Lunesta share nearing 40%

Share this article:
Sepracor president William O'Shea told analysts and investors that Lunesta's share of the sleep-aid market is nearing 40%, thanks to the company's aggressive direct-to-patient promotional efforts. The firm will now initiate “Phase Two” of its Lunesta promotion by increasing sales capacity and rolling out its expanded clinical database for the drug, he said in the company's first-half earnings report. The firm reported six-month Lunesta revenues of $277 million.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.